IQVIA Biotech Industry Opportunities Conference

AUM Biosciences presented its transformative oncology pipeline at the virtual Global Strategies for Accelerating Time to Market for Emerging Biopharmas event. This discussion will feature emerging biopharma and biotech companies leading the push of scientific breakthroughs in the Japan and Asia Pacific regions.

AUM Biosciences, a global clinical-stage biopharmaceutical company aiming to discover, acquire, and develop novel targeted therapeutics in oncology, was delighted for Vishal Doshi, CEO, to present a brief about AUM Biosciences’ portfolio of oncological medicines hosted by IQVIA Biotech on Thursday, May 27th.

To attend the event, please register HERE

About AUM Biosciences

AUM Biosciences is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. The management team has an extensive track record of selecting distinctive early stage assets, successfully exiting virtual biotech models, and have contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability and scalability.

For more information, please visit